A pyrazol compound having an acceptable inhibitory activity on ghlt1 or one of the drugs, including a pharmaceutical component, and a pharmaceutical use for type II diabetes is provided. 1. Characteristic requirement 1: a salt acceptable on a compound or a drug, characterized by (I) arilo c833318321；](Ii) cicloalquilo C o (iii) cicloalquenilo CN1 is 0, 1, 2, 3, or 4； R1 74919 has representative (I) halogen atom, (II) hydroxi, (III) carboxi, (4) a tar group c833261；(V) un grupo alquenilo C(vi) a C₂₋₈ alkynyl group,(vii) a C₁₋₆ alkoxy group,(VIII) one cycloquilo c83231；(ix) a C₁₋₆ haloalkyl group,(x) One c83231-8326；(xi) a C₁₋₆alkyl C₁₋₆ alkoxy group,(xii) a haloalkoxy C₁₋₆alkyl C₁₋₆ group,(xiii) a C₁₋₆sulfonylalkyl alkyl group,(xiv) a haloalkyl C₁₋₆sulfonylalkyl C₁₋₆,(xv) a halodyalkyl C₁₋₆aminoalkyl C₁₋₆ group,(xvi) a C₃₋₆alquinyl C₂₋₆ cycloalkyl group,(xvii) a C₁₋₆ haloalkoxy group,(xviii) a C₁₋₆ carboxyalkoxy group,(xix) a C₁₋₆sulfanyl alkyl group, (xx) a C₁₋₆ alkylsulfonyl group,(21) A c832183-83331-832626 halogenated tar group；(xxii) a C₁₋₈carbonyl alkyl group, (xxiii) a C₁₋₆oxycarbonyl alkyl group, (xxiv) a group represented by formula (2) where R⁵ is (a) a hydrogen atom or (b) a C₁ alkyl group ₋₆,e. R8310es (a) a group of c8321c831832626 or (b) a group of halogenated tar c8383331；(xxv) a C₆₋₁₀ alkyl group of saturated heterocycle (the saturated heterocycle is a 4-membered to 6-membered saturated heterocycle having 1 to 2 heteroatoms selected from nitrogen, oxygen, and sulfur),or (xxvi) a C₁₋₆ oxyalkyl group of a saturated heterocycle (the saturated heterocycle is a 4-membered to 6-membered saturated heterocycle having 1 to 2 heteroatoms selected from nitrogen, oxygen, and sulfur),with the proviso that when n1 is 2, 3, or 4, R¹ᵃ can be the same or different； R²ᵃ is (i) a C₁₋₈ hydroxyalkyl group,(ii) a C₃₋₈alkyl C₁₋₆ cycloalkyl group,(Iii) un grupo aril C1. Lease land No. c833218331 and 832626；(IV) a set of c8332626c83318321； 8320 from a saturated heterocycle (a
